Top physicians join internationally recognized leaders in pharmacogenetics and neuropsychiatry to advance personalized medicine in psychiatry.
August 18, 2011 – Chalfont, Pennsylvania – Genomind, LLC, a company focused on neuropsychiatric personalized medicine, announced additions to its leading Scientific Advisory Board, first named last September.
Added to the Scientific Advisory Board are Allan I. Levey, MD, PhD, Professor and Chairman of the Department of Neurology at Emory University and the Director of the Emory Alzheimer’s Disease Research Center; and Anil Malhotra, MD, Director of Psychiatry Research at the Zucker Hillside Hospital in Glen Oaks, NY and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine. Drs. Levey and Malhotra join Drs. Scott T. Aaronson, Maurizio Fava, Roy H. Perlis, and Stephen M. Stahl as thought leaders in pharmacogenetics and neuropsychiatry who are current members of Genomind’s Scientific Advisory Board.
“Our diagnostic assay was developed in close collaboration with the world’s leading experts in genetics and psychopharmacology.,” said Ronald I. Dozoretz, MD, Chairman and CEO of Genomind. “We believe our collaboration with these key opinion leaders creates an integrated approach to providing improved therapeutic options for clinicians and their patients.”
Allan I. Levey, MD, PhD
Dr. Levey is Professor and Chairman of the Department of Neurology at Emory University, and he is Director of the Emory Alzheimer’s Disease Research Center. He has secondary faculty appointments in the Departments of Pharmacology and Psychiatry and Behavioral Sciences.
Dr. Levey is an internationally recognized neurologist and neuroscientist known for his work in neurodegenerative disease. He has more than 250 research publications. His work has contributed to understanding the brain systems and mechanisms involved in neurodegenerative disorders including Alzheimer’s and Parkinson’s diseases and in identifying molecular targets for new therapeutic strategies. He has received several awards including the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association, the Heikkila Research Scholar Award from the National Parkinson Foundation, the Health Advancement Research Award from Community Health Charities and the Team Hope Award for Medical Leadership from the Huntington’s Disease Society of America. In addition, he was inducted into the Johns Hopkins Society of Scholars. Dr. Levey was also named an ISI Highly Cited Researcher in the field of Neuroscience and has consistently been listed among one of the Best Doctors in America.
Dr. Levey received a BS from the University of Michigan and an MD and PhD (Immunology) from the University of Chicago. He then trained in Neurology at Johns Hopkins, Molecular Biology at the National Institutes of Health, and then joined the Johns Hopkins faculty in the Departments of Neurology & Pathology. He has been at Emory University since 1991, where he has held a number of positions, including Director of Graduate Studies for the Neuroscience PhD Program, Founding Director of the Emory Center for Neurodegenerative Disease and Director of the Emory MD/PhD Training Program.
Anil Malhotra, MD
Dr. Malhotra is the Director of Psychiatry Research at the Zucker Hillside Hospital in Glen Oaks, NY and Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine (AECOM) in the Bronx, NY. Dr. Malhotra’s research group focuses on identifying the biological underpinnings of schizophrenia and the mechanism of action of antipsychotic drugs.
His group has identified a number of genes associated with increased risk for the disorder, determined their relationship with important clinical manifestations of illness, including cognitive impairment, and begun to examine the role of genetic factors in predicting individual responses to pharmacological treatment. His group published the first whole-genome-association study of schizophrenia, using new technology assessing hundreds of thousands of markers across the genome, as well as developed a new analytic strategy to assess these data. They also initiated a collaborative research project on early-onset psychiatric disorders with James Watson, PhD, co-discoverer of the DNA double helix, at Cold Spring Harbor Laboratory.
Dr. Malhotra is principal investigator of grants from the National Institute of Mental Health (NIMH), NARSAD and industry. He is a frequent speaker at international and national meetings, as well as giving numerous Grand Rounds presentations at academic institutions across the U.S. He is a member of the Editorial Boards of seven medical and scientific journals, participates in NIH study sections, and serves as the program chair for the only annual meeting dedicated to pharmacogenetics in psychiatry.
Dr. Malhotra completed his undergraduate studies at Cornell University in 1985 and received his MD from Wake Forest University in 1989. After residency training in psychiatry at Georgetown University, he completed a research fellowship at NIMH of the National Institutes of Health (NIH). He developed a research program in pharmacogenetics at the NIMH and was appointed the Chief of the Unit of Pharmacogenetics in the Experimental Therapeutics Branch in 1996. In 1998, Dr. Malhotra moved to the Zucker Hillside Hospital and AECOM and developed an internationally recognized molecular genetics program focused on the major neuropsychiatric disorders.
About Genomind, LLC: Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of personalized medicine into psychiatry by providing genetic information to better understand the patient. Genomind was founded by Ronald I Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. He also is founder of ValueOptions, one of the nation’s leading behavioral health and wellness companies. Dr Lombard, a neurologist, is co-founder of Genomind and is a nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.
For more information, contact:
Marketing Manager, Genomind